Expand all sections

Pembroliuzmab

Keytruda

Extended indication

Pembrolizumab (MK-3475) Subcutaneous (SC) Administered With Platinum Doublet Chemotherapy in Part

Therapeutic value

No estimate possible yet
Registration phase

Clinical trials

Product

Active substance

Pembroliuzmab
Domain

Oncology
Reason of inclusion

Indication extension
Main indication

Lung cancer
Extended indication

Pembrolizumab (MK-3475) Subcutaneous (SC) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC).
Proprietary name

Keytruda
Manufacturer

MSD
Portfolio holder

MSD
Mechanism of action

PD-1 / PD-L1 inhibitor
Route of administration

Subcutaneous
Therapeutical formulation

Injection
Budgetting framework

Intermural (MSZ)

Registration

Registration route

Centralised (EMA)
ATMP

No
Submission date

2024
Expected Registration

2025
Orphan drug

No
Registration phase

Clinical trials
Additional remarks 
Primary completion datum in april 2023.

Therapeutic value

Therapeutic value

No estimate possible yet
References 
NCT04956692

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Additional remarks 
Voor pembrolizumab is een financieel arrangement van toepassing tot 1 januari 2027. Aankomende indicatie uitbreidingen vallen onder deze overeenkomst, mits zij voldoen aan stand der wetenschap en praktijk.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.